{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:06:07Z","timestamp":1793120767683,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100023710","name":"Hellenic Institute for the Study of Sepsis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-53859-9","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T02:46:16Z","timestamp":1779590776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sepsis associated with Clostridioides difficile infection carries similar mortality to sepsis of other origin: a propensity score-matched analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"Christina","family":"Avgoustou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Psarrakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miltiades","family":"Kyprianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Dakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-3911","authenticated-orcid":false,"given":"Evangelos J.","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0187-512X","authenticated-orcid":false,"given":"Eleni","family":"Karakike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,24]]},"reference":[{"key":"53859_CR1","first-page":"1","volume-title":"ECDC. Annual epidemiological report for 2018\u2009\u2013\u20092020","author":"European Centre for Disease Prevention and Control","year":"2024","unstructured":"European Centre for Disease Prevention and Control. Clostridioides difficile infections. In: ECDC. Annual epidemiological report for 2018\u22122020. Stockholm: ECDC; 2024"},{"key":"53859_CR2","doi-asserted-by":"publisher","first-page":"e1914149","DOI":"10.1001\/jamanetworkopen.2019.14149","volume":"2","author":"NA Turner","year":"2019","unstructured":"Turner, N. A. et al. Epidemiologic Trends in Clostridioides difficile Infections in a Regional Community Hospital Network. JAMA Netw. Open. 2, e1914149 (2019).","journal-title":"JAMA Netw. Open."},{"key":"53859_CR3","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.cmi.2023.07.008","volume":"29","author":"A Boven","year":"2023","unstructured":"Boven, A. et al. Clostridioides difficile infection-associated cause-specific and all-cause mortality: a population-based cohort study. Clin. Microbiol. Infect. 29, 1424\u20131430 (2023).","journal-title":"Clin. Microbiol. Infect."},{"key":"53859_CR4","doi-asserted-by":"publisher","first-page":"154254","DOI":"10.1016\/j.jcrc.2023.154254","volume":"75","author":"JC Dionne","year":"2023","unstructured":"Dionne, J. C. et al. Clostridioides difficile infection in mechanically ventilated critically ill patients: a nested cohort study. J. Crit. Care. 75, 154254 (2023).","journal-title":"J. Crit. Care"},{"key":"53859_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.12788\/jhm.2816","volume":"12","author":"K Chatterjee","year":"2017","unstructured":"Chatterjee, K. et al. 2007\u20132013) of clostridium difficile infection in patients with septic shock: impact on outcome. J. Hosp. Med. 12, 717\u2013722 (2017).","journal-title":"J. Hosp. Med."},{"key":"53859_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/CCM.0000000000007089","volume":"54","author":"HC Prescott","year":"2026","unstructured":"Prescott, H. C. et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Crit. Care Med. 54, 725\u2013812 (2026).","journal-title":"Crit. Care Med."},{"key":"53859_CR7","doi-asserted-by":"publisher","first-page":"804949","DOI":"10.3389\/fmicb.2021.804949","volume":"12","author":"B Nibbering","year":"2021","unstructured":"Nibbering, B., Gerding, D. N., Kuijper, E. J., Zwittink, R. D. & Smits, W. K. Host immune responses to clostridioides difficile: toxins and beyond. Front. Microbiol. 12, 804949 (2021).","journal-title":"Front. Microbiol."},{"key":"53859_CR8","first-page":"1569","volume":"17","author":"M Montalto","year":"2013","unstructured":"Montalto, M. et al. Role of fecal calprotectin in gastrointestinal disorders. Eur. Rev. Med. Pharmacol. Sci. 17, 1569\u20131582 (2013).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"53859_CR9","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s10096-017-3080-y","volume":"36","author":"F Barbut","year":"2017","unstructured":"Barbut, F. et al. Faecal lactoferrin and calprotectin in patients with clostridium difficile infection: a case-control study. Eur. J. Clin. Microbiol. Infect. Dis. 36, 2423\u20132430 (2017).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"53859_CR10","doi-asserted-by":"publisher","first-page":"e106118","DOI":"10.1371\/journal.pone.0106118","volume":"9","author":"A Swale","year":"2014","unstructured":"Swale, A. et al. Calprotectin and lactoferrin faecal levels in patients with clostridium difficile infection (CDI): a prospective cohort study. PLoS One. 9, e106118. https:\/\/doi.org\/10.1371\/journal.pone.0106118 (2014).","journal-title":"PLoS One"},{"key":"53859_CR11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1186\/s12879-024-09394-x","volume":"24","author":"E Diehl-Wiesenecker","year":"2024","unstructured":"Diehl-Wiesenecker, E. et al. Blood calprotectin as a biomarker for infection and sepsis - the prospective CASCADE trial. BMC Infect. Dis. 24, 496 (2024).","journal-title":"BMC Infect. Dis."},{"key":"53859_CR12","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.cell.2020.08.002","volume":"182","author":"A Silvin","year":"2020","unstructured":"Silvin, A. et al. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell 182, 1401\u20131418 (2020).","journal-title":"Cell"},{"key":"53859_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13054-020-02897-4","volume":"24","author":"N Rovina","year":"2020","unstructured":"Rovina, N. et al. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit. Care. 24, 187 (2020).","journal-title":"Crit. Care"},{"key":"53859_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12916-017-0930-5","volume":"15","author":"E Kyriazopoulou","year":"2017","unstructured":"Kyriazopoulou, E. et al. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Med. 15, 172 (2017).","journal-title":"BMC Med."},{"key":"53859_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fimmu.2019.00055","volume":"10","author":"E Karakike","year":"2019","unstructured":"Karakike, E. & Giamarellos-Bourboulis, E. J. Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis. Front. Immunol. 10, 55 (2019).","journal-title":"Front. Immunol."},{"key":"53859_CR16","doi-asserted-by":"publisher","first-page":"100817","DOI":"10.1016\/j.xcrm.2022.100817","volume":"3","author":"K Leventogiannis","year":"2022","unstructured":"Leventogiannis, K. et al. Toward personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial. Cell. Rep. Med. 3, 100817 (2022).","journal-title":"Cell. Rep. Med."},{"key":"53859_CR17","doi-asserted-by":"publisher","first-page":"105414","DOI":"10.1016\/j.ebiom.2024.105414","volume":"109","author":"EJ Giamarellos-Bourboulis","year":"2024","unstructured":"Giamarellos-Bourboulis, E. J. et al. Interferon-gamma driven elevation of CXCL9: a new sepsis endotype independently associated with mortality. EBioMedicine 109, 105414 (2024).","journal-title":"EBioMedicine"},{"key":"53859_CR18","doi-asserted-by":"publisher","first-page":"102533","DOI":"10.1016\/j.xcrm.2025.102533","volume":"7","author":"C Psarrakis","year":"2026","unstructured":"Psarrakis, C. et al. A randomized controlled trial of precision bezlotoxumab treatment for Clostridioides difficile infection. Cell. Rep. Med. 7, 102533 (2026).","journal-title":"Cell. Rep. Med."},{"key":"53859_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer, M. et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315, 801\u2013810 (2016).","journal-title":"JAMA"},{"key":"53859_CR20","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s00134-023-07127-3","volume":"49","author":"EJ Giamarellos-Bourboulis","year":"2023","unstructured":"Giamarellos-Bourboulis, E. J. et al. Sepsis, a call for inclusion in the work plan of the european center for disease prevention and control. Intensive Care Med. 49, 1138\u20131142 (2023).","journal-title":"Intensive Care Med."},{"key":"53859_CR21","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/cid\/cix1112","volume":"66","author":"T Watson","year":"2018","unstructured":"Watson, T. et al. Evaluating the risk factors for hospital-onset clostridium difficile infections in a large healthcare system. Clin. Infect. Dis. 66, 1957\u20131959 (2018).","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl 2","key":"53859_CR22","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","volume":"27","author":"J van Prehn","year":"2021","unstructured":"van Prehn, J. et al. European society of clinical microbiology and infectious diseases: 2021 update on the treatment guidance document for clostridioides difficile infection in adults. Clin. Microbiol. Infect. 27 (Suppl 2), S1\u2013S21 (2021).","journal-title":"Clin. Microbiol. Infect."},{"key":"53859_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa1602615","volume":"376","author":"MH Wilcox","year":"2017","unstructured":"Wilcox, M. H. et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl. J. Med. 376, 305\u2013317 (2017).","journal-title":"N Engl. J. Med."},{"key":"53859_CR24","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","volume":"116","author":"CR Kelly","year":"2021","unstructured":"Kelly, C. R. et al. ACG clinical guidelines: prevention, diagnosis, and treatment of clostridioides difficile infections. Am. J. Gastroenterol. 116, 1124\u20131147 (2021).","journal-title":"Am. J. Gastroenterol."},{"key":"53859_CR25","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1097\/MIB.0000000000000908","volume":"22","author":"M Fischer","year":"2016","unstructured":"Fischer, M. et al. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory clostridium difficile infection in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 22, 2402\u20132409 (2016).","journal-title":"Inflamm. Bowel Dis."},{"key":"53859_CR26","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1001\/jama.2023.4314","volume":"329","author":"T Louie","year":"2023","unstructured":"Louie, T. et al. VE303, a defined bacterial consortium, for prevention of recurrent clostridioides difficile infection: a randomized clinical trial. JAMA 329, 1356\u20131366 (2023).","journal-title":"JAMA"},{"key":"53859_CR27","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.cmi.2022.12.019","volume":"29","author":"SM Wingen-Heimann","year":"2023","unstructured":"Wingen-Heimann, S. M. et al. Clostridioides difficile infection (CDI): a pan-european multi-center cost and resource utilization study, results from the combatting bacterial resistance in europe CDI (COMBACTE-CDI). Clin. Microbiol. Infect. 29, 651. e1-651.e8 (2023).","journal-title":"Clin. Microbiol. Infect."},{"key":"53859_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/antibiotics13040367","volume":"13","author":"M Stoian","year":"2024","unstructured":"Stoian, M. et al. COVID-19 and Clostridioides difficile Coinfection Analysis in the Intensive Care Unit. Antibiotics (Basel). 13, 367 (2024).","journal-title":"Antibiotics (Basel)"},{"key":"53859_CR29","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.3390\/diagnostics12123196","volume":"12","author":"A Boeriu","year":"2022","unstructured":"Boeriu, A. et al. The Impact of Clostridioides Difficile Infection in Hospitalized Patients: What Changed during the Pandemic? Diagnostics (Basel). 12, 3196 (2022).","journal-title":"Diagnostics (Basel)"},{"key":"53859_CR30","doi-asserted-by":"publisher","first-page":"1045636","DOI":"10.3389\/fcimb.2022.1045636","volume":"12","author":"RY Gao","year":"2022","unstructured":"Gao, R. Y. et al. Calprotectin as a diagnostic marker for sepsis: a meta-analysis. Front. Cell. Infect. Microbiol. 12, 1045636 (2022).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"53859_CR31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1128\/CVI.00770-13","volume":"21","author":"C Darkoh","year":"2014","unstructured":"Darkoh, C. et al. Colonic immunopathogenesis of clostridium difficile infections. Clin. Vaccine Immunol. 21, 509\u2013517 (2014).","journal-title":"Clin. Vaccine Immunol."},{"key":"53859_CR32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.anaerobe.2019.03.006","volume":"56","author":"J Hibbard","year":"2019","unstructured":"Hibbard, J., Jiang, Z. D. & DuPont, H. L. Fecal calprotectin and fecal indole predict outcome of fecal microbiota transplantation in subjects with recurrent clostridium difficile infection. Anaerobe 56, 102\u2013105 (2019).","journal-title":"Anaerobe"},{"key":"53859_CR33","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1111\/jgh.15072","volume":"35","author":"A Gallo","year":"2020","unstructured":"Gallo, A. et al. Fecal calprotectin and need of multiple microbiota trasplantation infusions in clostridium difficile infection. J. Gastroenterol. Hepatol. 35, 1909\u20131915 (2020).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"53859_CR34","doi-asserted-by":"publisher","first-page":"1237500","DOI":"10.3389\/fcimb.2023.1237500","volume":"13","author":"S V\u00e1zquez-Cuesta","year":"2023","unstructured":"V\u00e1zquez-Cuesta, S. et al. Microbiome profile and calprotectin levels as markers of risk of recurrent clostridioides difficile infection. Front. Cell. Infect. Microbiol. 13, 1237500 (2023).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"53859_CR35","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jointm.2024.01.001","volume":"4","author":"JM Cavaillon","year":"2024","unstructured":"Cavaillon, J. M., Chousterman, B. G. & Skirecki, T. Compartmentalization of the inflammatory response during bacterial sepsis and severe COVID-19. J. Intensive Med. 4, 326\u2013340 (2024).","journal-title":"J. Intensive Med."},{"key":"53859_CR36","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1097\/MEG.0000000000001578","volume":"32","author":"A Abdel-Razik","year":"2020","unstructured":"Abdel-Razik, A. et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: novel predictors. Eur. J. Gastroenterol. Hepatol. 32, 718\u2013726 (2020).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"53859_CR37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cca.2015.01.031","volume":"451","author":"JR Delanghe","year":"2015","unstructured":"Delanghe, J. R. & Speeckaert, M. M. Translational research and biomarkers in neonatal sepsis. Clin. Chim. Acta. 451, 46\u201364 (2015).","journal-title":"Clin. Chim. Acta"},{"key":"53859_CR38","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.3390\/ijms23094894","volume":"23","author":"G Kassianidis","year":"2022","unstructured":"Kassianidis, G. et al. Calprotectin and imbalances between acute-phase mediators are associated with critical illness in COVID-19. Int. J. Mol. Sci. 23, 4894 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"53859_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.chom.2015.06.011","volume":"18","author":"MC Abt","year":"2015","unstructured":"Abt, M. C. et al. Innate immune defenses mediated by two ILC subsets are critical for protection against acute clostridium difficile infection. Cell. Host Microbe. 18, 27\u201337 (2015).","journal-title":"Cell. Host Microbe"},{"key":"53859_CR40","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/imm.12700","volume":"150","author":"AJ McDermott","year":"2017","unstructured":"McDermott, A. J. et al. Role of interferon-\u03b3 and inflammatory monocytes in driving colonic inflammation during acute clostridium difficile infection in mice. Immunology 150, 468\u2013477 (2017).","journal-title":"Immunology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53859-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53859-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53859-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:03:28Z","timestamp":1785452608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53859-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["53859"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-53859-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,24]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EJ Giamarellos-Bourboulis reports honoraria from Abbott Products Operations, bioM\u00e9rieux, Brahms GmbH, GSK, InflaRx GmbH, Sobi and Xbiotech Inc; independent educational grants from Abbott Products Operations, bioM\u00e9rieux Inc, Johnson & Johnson, MSD, UCB, Swedish Orphan Biovitrum AB; and funding from the Horizon 2020 European Grants ImmunoSep and RISCinCOVID and the Horizon Health grants EPIC-CROWN-2, POINT and Homi-Lung (granted to the Hellenic Institute for the Study of Sepsis).\u00a0The other authors do not declare any competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Clinicaltrials.gov NCT05304715, NCT02573571.","order":2,"name":"Ethics","label":"Source cohorts","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study protocol for the observational SPECIFY study (NCT02573571) was approved by the Institutional Ethics Committees of the participating hospitals, and a detailed list of granted approvals is provided in the\n                      Supplementary Table S1\n                      online. The interventional BEYOND trial (NCT05304715) was granted approval by the National Ethics Committee-EED 178\/21, 19-11-2021 and the National Organization for Medicines IS166-21\/24-11-2021. Regarding the prospective registry, the study protocol was approved by the Institutional Ethics Committees of the participating hospitals, and a detailed list of granted approvals is provided in the\n                      Supplementary Table S2\n                      online.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients in each study were enrolled after written informed consent provided by themselves or their first-degree relatives, in case of inability to provide consent.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23689"}}